Biogen Inc. (NASDAQ:BIIB) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:45 PM ET
Company Participants
Chris Viehbacher – President and CEO
Conference Call Participants
Chris Schott – JPMorgan
Chris Schott
I think we are ready to kick off the next session here. So good morning, everybody. I’m Chris Schott from JPMorgan, and I’m pleased to be introducing Biogen today. From the company, we have Chris Viehbacher, the company’s President and CEO. Chris has been CEO for a little bit over 2 years now. So looking forward to the presentation here. We’re going to do about a 20-minute presentation, and then we’re going to go over to Q&A from there.
So I’m going to turn it over to Chris. We’re going to — if some of the folks on — yes.
Chris Viehbacher
All right. Good morning, everyone. So let’s just see. Here we go. So we covered that. So new year, new opportunities. What we’re principally focused on, obviously, in the near term is really executing strongly on the 4 product launches that we did last year with LEQEMBI, with SKYCLARYS, with ZURZUVAE and with QALSODY.
What I’d like to talk about this morning is where is Biogen going longer term? And there’s really 3 main areas of focus here. The first is nothing that we have seen so far with the launch of LEQEMBI dissuades from the fact that there is still significant unmet need in Alzheimer’s, and therefore, there is also a significant commercial opportunity. And we’re doubling down on Alzheimer’s.
The second is, I think in 2024, we made significant progress on our pipeline. And in fact, I think we have really seen an awful lot of conviction and confidence in our pipeline, at least, internally from what we see. And we all know all of the uncertainties around pipelines, but I think
Read the full article here